{"id":"NCT01422304","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)","officialTitle":"A Randomized, Controlled, Parallel-group, Double-blind Trial of Sugammadex or Usual Care (Neostigmine or Spontaneous Recovery) for Reversal of Rocuronium- or Vecuronium-induced Neuromuscular Blockade in Patients Receiving Thromboprophylaxis and Undergoing Hip Fracture Surgery or Joint (Hip/Knee) Replacement (Protocol No. P07038)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10-12","primaryCompletion":"2012-09-26","completion":"2012-09-26","firstPosted":"2011-08-23","resultsPosted":"2013-10-30","lastUpdate":"2021-02-12"},"enrollment":1198,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Neuromuscular Blockade","Arthroplasty, Replacement, Hip","Arthroplasty, Replacement, Knee","Blood Coagulation","Antithrombotic Agents"],"interventions":[{"type":"DRUG","name":"Sugammadex","otherNames":["SCH 900616, MK-8616"]},{"type":"DRUG","name":"neostigmine and glycopyrrolate or atropine","otherNames":[]},{"type":"DRUG","name":"Placebo to neostigmine","otherNames":[]},{"type":"DRUG","name":"Placebo to sugammadex","otherNames":[]}],"arms":[{"label":"Sugammadex","type":"EXPERIMENTAL"},{"label":"Usual Care","type":"EXPERIMENTAL"}],"summary":"This study will assess the effect of reversal of neuromuscular blockade with sugammadex compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of post-surgical bleeding events and on coagulation parameters in participants undergoing hip fracture surgery or joint (hip/knee) replacement surgery with neuromuscular blockage induced by rocuronium or vecuronium.","primaryOutcome":{"measure":"Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 24 Hours After Study Drug Administration","timeFrame":"Up to 24 hours post study drug administration","effectByArm":[{"arm":"Sugammadex","deltaMin":17,"sd":null},{"arm":"Usual Care","deltaMin":24,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25208233"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":596},"commonTop":["Procedural pain","Constipation","Nausea","Pain","Sleep disorder"]}}